Clinical Trials Browser

Carcinoma, Squamous Cell × cabozantinib × Gastrointestinal × Clear all

NCT05007613 2025-01-01

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Metastasis